Efficacy and Safety of Rezūm Water Vapor Thermal Ablation in Large and Small Prostates: A Multicenter Comparative Analysis of 2,725 Patients
Abstract
BACKGROUND
Rezūm water vapor therapy is well established for benign prostatic hyperplasia in prostates <80 cc; however, evidence in larger glands remains limited despite increasing demand for minimally invasive alternatives to conventional surgery. We compared outcomes after Rezūm therapy in patients with large versus small prostates.
STUDY DESIGN
In this multicenter retrospective study, 2,725 patients undergoing Rezūm therapy across 5 centers were stratified by prostate volume: large prostate (LP, ≥80 cc; n=993) and small prostate (SP, <80 cc; n=1,732). Primary outcomes were 6-month changes in International Prostate Symptom Score (IPSS), IPSS Quality of Life (QoL), peak urinary flow rate (Qmax), and post-void residual (PVR). Secondary outcomes included Sexual Health Inventory for Men (SHIM) scores, complications, and retreatment rates.
RESULTS
At 6 months, LP and SP cohorts achieved comparable improvements in IPSS (41.4% vs 41.9%; p=0.958), QoL (50.0% vs 50.0%; p=0.394), and Qmax (122.2% vs 118.2%; p=0.62). LP patients experienced greater reduction in PVR (68.8% vs 24.0%; p<0.001). SHIM scores remained stable in both groups despite a significant between-group difference. Complication rates were similar (5.0% vs 4.9%; p=0.559). Over a median follow-up of 41 months, LP patients had lower surgical retreatment rates than SP patients (3.6% vs 7.2%; p<0.001).
CONCLUSIONS
In this large multicenter cohort, Rezūm therapy provided comparable symptomatic and flow-rate improvement in…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 2,725 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.